

Supplementary Tables

Theme 1: Screening practice

STable 1. Pandemic-related updates to practice/institutional/jurisdictional procedures (n = 510)

Question number & content	Categories	n (%)
Q11 Allowance of in-person consultations during peak pandemic	Yes	378 (74.1)
	No	99 (19.4)
	<i>Don't know</i>	13 (2.6)
	<i>Not applicable to my practice</i>	20 (3.9)
Q12 Informed about latest recommendations/guidelines for cervical cancer screening during peak pandemic	Yes	274 (53.7)
	No	164 (32.2)
	<i>Don't know</i>	62 (12.2)
	<i>Not applicable to my practice</i>	10 (2.0)
Q13 Frequency of updates to recommendations/guidelines that modify scheduling/performing cervical cancer screening	Every week	18 (3.5)
	Every 2 weeks	48 (9.4)
	Every month	101 (19.8)
	Every 2 months	58 (11.4)
	>2 months	118 (23.1)
	Never	92 (18.0)
	<i>Don't know</i>	65 (12.8)
<i>Not applicable to my practice</i>	10 (2.0)	

STable 2. Screening test practices (n = 469)

Question number & content	Categories	n (%)	
Q14 Type of test used for primary cervical cancer screening	Pap test	Yes	357 (76.1)
		No	61 (13.0)
		<i>Don't know</i>	37 (7.9)
		<i>Not applicable to my practice</i>	14 (3.0)
	HPV test	Yes	154 (32.8)
		No	230 (49.0)
		<i>Don't know</i>	36 (7.7)
		<i>Not applicable to my practice</i>	49 (10.5)
	HPV/Pap co-test	Yes	119 (25.4)
		No	262 (55.9)
		<i>Don't know</i>	43 (9.2)
		<i>Not applicable to my practice</i>	45 (9.6)
Q15 Change in number of screening tests compared to pre-COVID-19	Pap test	Decrease $\geq 75\%$	74 (15.8)
		Decrease 26-74%	117 (25.0)
		Decrease $\leq 25\%$	95 (20.3)
		Unaffected	82 (17.5)
		Increase $\leq 25\%$	24 (5.1)
		Increase 26-74%	18 (3.8)
		Increase $\geq 75\%$	9 (1.9)
		<i>Don't know</i>	37 (7.9)
	<i>Not applicable to my practice</i>	13 (2.8)	
	HPV test	Decrease $\geq 75\%$	23 (4.9)
		Decrease 26-74%	31 (6.6)
		Decrease $\leq 25\%$	33 (7.0)
Unaffected		91 (19.4)	
Increase $\leq 25\%$		34 (7.3)	
Increase 26-74%		30 (6.4)	
Increase $\geq 75\%$		11 (2.4)	
<i>Don't know</i>		43 (9.2)	
<i>Not applicable to my practice</i>	173 (37.0)		
HPV/Pap co-test	Decrease $\geq 75\%$	18 (3.8)	
	Decrease 26-74%	36 (7.7)	
	Decrease $\leq 25\%$	35 (7.5)	
	Unaffected	70 (14.9)	
	Increase $\leq 25\%$	36 (7.7)	
	Increase 26-74%	22 (4.7)	
	Increase $\geq 75\%$	12 (2.6)	
	<i>Don't know</i>	39 (8.3)	
<i>Not applicable to my practice</i>	201 (42.9)		
Q16 Delays in scheduling of tests	Pap test	Yes	267 (56.9)
		No	132 (28.1)
		<i>Don't know</i>	50 (10.7)
		<i>Not applicable to my practice</i>	20 (4.3)
	HPV test	Yes	106 (22.6)
		No	116 (24.7)
		<i>Don't know</i>	57 (12.2)
		<i>Not applicable to my practice</i>	190 (40.5)
HPV/Pap co-test	Yes	102 (21.8)	
	No	93 (19.8)	
	<i>Don't know</i>	58 (12.4)	
	<i>Not applicable to my practice</i>	216 (46.1)	

HPV: human papillomavirus

STable 3. Cancellation and postponement of scheduled screening tests by type of test

Question number & content (number of responses)	Categories	n (%)	
Q17 Percentage of scheduled screening tests that have been cancelled (n = 469)	Pap test	0%	76 (16.2)
		1-24%	145 (31.0)
		25-49%	80 (17.1)
		50-74%	45 (9.6)
		≥75%	49 (10.5)
		<i>Don't know</i>	<i>54 (11.5)</i>
		<i>Not applicable to my practice</i>	<i>20 (4.3)</i>
	HPV test	0%	65 (13.9)
		1-24%	41 (8.7)
		25-49%	52 (11.1)
		50-74%	33 (7.0)
		≥75%	37 (7.9)
		<i>Don't know</i>	<i>56 (11.9)</i>
	HPV/Pap co-test	<i>Not applicable to my practice</i>	<i>185 (39.5)</i>
		0%	49 (10.5)
		1-24%	43 (9.2)
		25-49%	38 (8.1)
		50-74%	39 (8.3)
		≥75%	42 (9.0)
Pap test	<i>Don't know</i>	<i>45 (9.6)</i>	
	<i>Not applicable to my practice</i>	<i>213 (45.4)</i>	
	0%	29 (6.2)	
	1-24%	119 (25.4)	
	25-49%	100 (21.4)	
	50-74%	75 (16.0)	
	≥75%	78 (16.7)	
	<i>Don't know</i>	<i>48 (10.3)</i>	
HPV test	<i>Not applicable to my practice</i>	<i>19 (4.1)</i>	
	0%	49 (10.5)	
	1-24%	49 (10.5)	
	25-49%	55 (11.8)	
	50-74%	36 (7.7)	
	≥75%	45 (9.6)	
	<i>Don't know</i>	<i>47 (10.0)</i>	
	<i>Not applicable to my practice</i>	<i>187 (40.0)</i>	
HPV/Pap co-test	0%	44 (9.4)	
	1-24%	45 (9.6)	
	25-49%	49 (10.5)	
	50-74%	43 (9.2)	
	≥75%	32 (6.8)	
	<i>Don't know</i>	<i>45 (9.6)</i>	
	<i>Not applicable to my practice</i>	<i>210 (44.9)</i>	
Pap test	1 week to <2 weeks	15 (3.2)	
	2 weeks to <4 weeks	43 (9.2)	
	1 month to <2 months	78 (16.7)	
	2 months to <4 months	128 (27.4)	
	4 months to <6 months	87 (18.7)	
	>6 months	47 (10.1)	
	<i>Don't know</i>	<i>36 (7.7)</i>	
	<i>Not applicable to my practice</i>	<i>33 (7.1)</i>	
	1 week to <2 weeks	22 (4.7)	
	2 weeks to <4 weeks	31 (6.6)	
1 month to <2 months	46 (9.9)		

Question number & content (number of responses)	Categories	n (%)	
Q19 Deferral period of postponed testing appointments (n = 467)	HPV test	2 months to <4 months	48 (10.3)
		4 months to <6 months	35 (7.5)
		>6 months	31 (6.6)
		<i>Don't know</i>	42 (9.0)
		<i>Not applicable to my practice</i>	212 (45.4)
	HPV/Pap co-test	1 week to <2 weeks	16 (3.4)
		2 weeks to <4 weeks	27 (5.8)
		1 month to <2 months	30 (6.4)
		2 months to <4 months	46 (9.9)
		4 months to <6 months	47 (10.1)
		>6 months	31 (6.6)
		<i>Don't know</i>	36 (7.7)
		<i>Not applicable to my practice</i>	234 (50.1)

HPV: human papillomavirus

STable 4. Pandemic-related delays in forwarding screening test samples to the lab (n = 467)

Question number & content	Categories	n (%)	
Q20 Delay in forwarding tests to labs for processing	Pap test	Yes	70 (15.0)
		No	323 (69.2)
		<i>Don't know</i>	57 (12.2)
		<i>Not applicable to my practice</i>	17 (3.6)
	HPV test	Yes	73 (15.6)
		No	164 (35.1)
		<i>Don't know</i>	42 (9.0)
		<i>Not applicable to my practice</i>	188 (40.3)
	HPV/Pap co-test	Yes	65 (13.9)
		No	126 (27.0)
		<i>Don't know</i>	58 (12.4)
		<i>Not applicable to my practice</i>	218 (46.7)
Q21 Delay period in forwarding test samples to lab	Pap test	1 week to <2 weeks	73 (15.6)
		2 weeks to <4 weeks	32 (6.9)
		1 month to <2 months	45 (9.6)
		2 months to <4 months	39 (8.4)
		4 months to <6 months	24 (5.1)
		>6 months	6 (1.3)
		<i>Don't know</i>	63 (13.5)
		<i>Not applicable to my practice</i>	185 (39.6)
	HPV test	1 week to <2 weeks	35 (7.5)
		2 weeks to <4 weeks	29 (6.2)
		1 month to <2 months	32 (6.9)
		2 months to <4 months	28 (6.0)
4 months to <6 months		34 (7.3)	
>6 months		22 (4.7)	
<i>Don't know</i>	40 (8.6)		
<i>Not applicable to my practice</i>	247 (52.9)		
HPV/Pap co-test	1 week to <2 weeks	32 (6.9)	
	2 weeks to <4 weeks	25 (5.4)	
	1 month to <2 months	24 (5.1)	
	2 months to <4 months	37 (7.9)	
	4 months to <6 months	27 (5.8)	
	>6 months	18 (3.9)	
	<i>Don't know</i>	43 (9.2)	
<i>Not applicable to my practice</i>	261 (55.9)		

HPV: human papillomavirus

STable 5. Professional opinions on HPV self-sampling (n = 455)

Question number & content	Categories	n (%)
Q22 COVID-19 to encourage/facilitate/accelerate implementation of HPV self-sampling in cervical cancer screening programs	Yes	150 (33.0)
	No	143 (31.4)
	Maybe	162 (35.6)
Q23 In favor of implementing HPV self-sampling as alternative screening method in practice	Yes	228 (50.1)
	No	123 (27.0)
	Maybe	104 (22.9)

HPV: human papillomavirus

STable 6. Changes in colposcopy appointments

Question number & content (number of responses)	Categories	n (%)	
Q24 Changes in number of colposcopy-biopsy procedures compared to pre-COVID-19 (n = 452)	Decrease $\geq 75\%$	21 (4.7)	
	Decrease 26-74%	61 (13.5)	
	Decrease $\leq 25\%$	87 (19.3)	
	Unaffected	40 (8.9)	
	Increase $\leq 25\%$	24 (5.3)	
	Increase 26-74%	10 (2.2)	
	Increase $\geq 75\%$	6 (1.3)	
	<i>Don't know</i>	34 (7.5)	
	<i>Not applicable to my practice</i>	169 (37.4)	
Q25 Cancellations of colposcopy appointments (n = 452)	Yes	114 (25.2)	
	No	95 (21.0)	
	<i>Don't know</i>	72 (15.9)	
	<i>Not applicable to my practice</i>	171 (37.8)	
Q26 Percentage of cancelled colposcopy appointments (n = 114)	Cancelled by physician or provider's institution	0%	5 (4.4)
		1-24%	45 (39.5)
		25-49%	30 (26.3)
		50-74%	16 (14.0)
		$\geq 75\%$	11 (9.7)
	<i>Don't know</i>	7 (6.1)	
	Cancelled by patient	0%	6 (5.3)
		1-24%	41 (36.0)
		25-49%	23 (20.2)
		50-74%	21 (18.4)
$\geq 75\%$		14 (12.3)	
<i>Don't know</i>	9 (7.9)		
Q27 Postponements in scheduling of colposcopy appointments (n = 452)	Yes	167 (37.0)	
	No	68 (15.0)	
	<i>Don't know</i>	44 (9.7)	
	<i>Not applicable to my practice</i>	173 (38.3)	
Q28 Percentage of postponed colposcopy appointments (n = 167)	Postponed by physician or provider's institution	0%	2 (1.2)
		1-24%	47 (28.1)
		25-49%	40 (24.0)
		50-74%	43 (25.8)
		$\geq 75\%$	25 (15.0)
	<i>Don't know</i>	10 (6.0)	
	Postponed by patient	0%	7 (4.2)
		1-24%	62 (37.1)
		25-49%	44 (26.4)
		50-74%	23 (13.8)
$\geq 75\%$		14 (8.4)	
<i>Don't know</i>	17 (10.2)		
Q29 Length of deferral period of postponed colposcopy appointments (n = 167)	1 week to <2 weeks	6 (3.6)	
	2 weeks to <4 weeks	18 (10.8)	
	1 month to <2 months	44 (26.4)	
	2 months to <4 months	59 (35.3)	
	4 months to <6 months	25 (15.0)	
	>6 months	9 (5.4)	
<i>Don't know</i>	6 (3.6)		

STable 7. Changes in follow-up appointments

Question number & content (number of responses)	Categories	n (%)	
Q30 Delay in follow-up of patients following test results (n = 446)	Abnormal cytology	Yes	121 (27.1)
		No	251 (56.3)
		<i>Don't know</i>	52 (11.7)
		<i>Not applicable to my practice</i>	22 (4.9)
	High-grade lesions	Yes	97 (21.8)
		No	257 (57.6)
		<i>Don't know</i>	57 (12.8)
	Positive HPV test	<i>Not applicable to my practice</i>	35 (7.9)
		Yes	75 (16.8)
		No	191 (42.8)
	Positive HPV self-sampling	<i>Don't know</i>	58 (13.0)
		<i>Not applicable to my practice</i>	122 (27.4)
Yes		55 (12.3)	
Q31 Cancellations of follow-up appointments (n = 445)	No	96 (21.5)	
	<i>Don't know</i>	52 (11.7)	
	<i>Not applicable to my practice</i>	243 (54.5)	
	Yes	148 (33.3)	
Q32 Percentage of cancelled follow-up appointments (n = 148)	Cancelled by physician or provider's institution	No	170 (38.2)
		<i>Don't know</i>	97 (21.8)
		<i>Not applicable to my practice</i>	30 (6.7)
		0%	25 (16.9)
		1-24%	58 (39.2)
		25-49%	29 (19.6)
	Cancelled by patient	50-74%	19 (12.8)
		≥75%	9 (6.1)
		<i>Don't know</i>	8 (5.4)
		0%	3 (2.0)
Converted to telemedicine	1-24%	61 (41.2)	
	25-49%	35 (23.7)	
	50-74%	28 (18.9)	
	≥75%	15 (10.1)	
	<i>Don't know</i>	6 (4.1)	
	0%	24 (16.2)	
Q33 Postponements in scheduling of follow-up appointments (n = 445)	Yes	238 (53.5)	
	No	123 (27.6)	
	<i>Don't know</i>	55 (12.4)	
	<i>Not applicable to my practice</i>	29 (6.5)	
Postponed by physician or provider's institution	0%	21 (8.8)	
	1-24%	84 (35.3)	
	25-49%	49 (20.6)	
	50-74%	40 (16.8)	
	≥75%	28 (11.8)	
	<i>Don't know</i>	16 (6.7)	
Q34 Percentage of postponed follow-up appointments (n=238)	Postponed by patient	0%	6 (2.5)
		1-24%	98 (41.2)
		25-49%	59 (24.8)
		50-74%	36 (15.1)

	≥75%	19 (8.0)
	<i>Don't know</i>	20 (8.4)
Converted to telemedicine	0%	48 (20.2)
	1-24%	51 (21.4)
	25-49%	41 (17.2)
	50-74%	42 (17.6)
	≥75%	29 (12.2)
	<i>Don't know</i>	27 (11.3)
Q35 Length of deferral period of postponed follow-up appointments (n=238)	1 week to <2 weeks	11 (4.6)
	2 weeks to <4 weeks	39 (16.4)
	1 month to <2 months	67 (28.2)
	2 months to <4 months	69 (29.0)
	4 months to <6 months	35 (14.7)
	>6 months	9 (3.8)
	<i>Don't know</i>	8 (3.4)

HPV: human papillomavirus

STable 8. Pandemic-related delays in receiving test results from lab (n = 445)

Question number & content	Categories	n (%)	
Q36 Delay in receiving test results from lab	Pap test	Yes	94 (21.1)
		No	273 (61.4)
		<i>Don't know</i>	65 (14.6)
		<i>Not applicable to my practice</i>	13 (2.9)
	HPV test	Yes	86 (19.3)
		No	130 (29.2)
		<i>Don't know</i>	63 (14.2)
		<i>Not applicable to my practice</i>	166 (37.3)
	HPV/Pap co-test	Yes	54 (12.1)
		No	116 (26.1)
		<i>Don't know</i>	76 (17.1)
		<i>Not applicable to my practice</i>	199 (44.7)
Q37 Delay period in receiving test samples from lab	Pap test	1 week to <2 weeks	62 (13.9)
		2 weeks to <4 weeks	49 (11.0)
		1 month to <2 months	58 (13.0)
		2 months to <4 months	45 (10.1)
		4 months to <6 months	28 (6.3)
		>6 months	15 (3.4)
		<i>Don't know</i>	56 (12.6)
		<i>Not applicable to my practice</i>	132 (29.7)
	HPV test	1 week to <2 weeks	30 (6.8)
		2 weeks to <4 weeks	31 (7.0)
		1 month to <2 months	37 (8.3)
		2 months to <4 months	35 (7.9)
4 months to <6 months		35 (7.9)	
>6 months		17 (3.8)	
<i>Don't know</i>	42 (9.4)		
<i>Not applicable to my practice</i>	218 (49.0)		
HPV/Pap co-test	1 week to <2 weeks	29 (6.5)	
	2 weeks to <4 weeks	23 (5.2)	
	1 month to <2 months	28 (6.3)	
	2 months to <4 months	32 (7.2)	
	4 months to <6 months	31 (7.0)	
	>6 months	19 (4.3)	
	<i>Don't know</i>	51 (11.5)	
<i>Not applicable to my practice</i>	232 (52.1)		

HPV: human papillomavirus

Theme 2: Treatment of pre-cancerous lesions and cancer

STable 9. Changes observed in number of treatment procedures, by treatment type (n = 431)

Variable	Categories	n (%)	
Q38 Changes in number of treatment procedures	Cold knife conization	Decrease $\geq 75\%$	14 (3.3)
		Decrease 26-74%	25 (5.8)
		Decrease $\leq 25\%$	29 (6.7)
		Unaffected	54 (12.5)
		Increase $\leq 25\%$	28 (6.5)
		Increase 26-74%	27 (6.3)
		Increase $\geq 75\%$	13 (3.0)
		<i>Don't know</i>	41 (9.5)
	<i>Not applicable to my practice</i>		200 (46.4)
	Other excisional	Decrease $\geq 75\%$	14 (3.3)
		Decrease 26-74%	32 (7.4)
		Decrease $\leq 25\%$	40 (9.3)
		Unaffected	55 (12.8)
		Increase $\leq 25\%$	32 (7.4)
		Increase 26-74%	23 (5.3)
		Increase $\geq 75\%$	12 (2.8)
	<i>Don't know</i>	34 (7.9)	
	<i>Not applicable to my practice</i>		189 (43.9)
	Ablative procedures	Decrease $\geq 75\%$	15 (3.5)
		Decrease 26-74%	24 (5.6)
Decrease $\leq 25\%$		29 (6.7)	
Unaffected		47 (10.9)	
Increase $\leq 25\%$		31 (7.2)	
Increase 26-74%		24 (5.6)	
Increase $\geq 75\%$		15 (3.5)	
<i>Don't know</i>	36 (8.4)		
<i>Not applicable to my practice</i>		210 (48.7)	
Hysterectomy	Decrease $\geq 75\%$	20 (4.6)	
	Decrease 26-74%	36 (8.4)	
	Decrease $\leq 25\%$	47 (10.9)	
	Unaffected	40 (9.3)	
	Increase $\leq 25\%$	26 (6.0)	
	Increase 26-74%	19 (4.4)	
	Increase $\geq 75\%$	13 (3.0)	
<i>Don't know</i>	37 (8.6)		
<i>Not applicable to my practice</i>		193 (44.8)	
Chemotherapy	Decrease $\geq 75\%$	6 (1.4)	
	Decrease 26-74%	12 (2.8)	
	Decrease $\leq 25\%$	29 (6.7)	
	Unaffected	47 (10.9)	
	Increase $\leq 25\%$	30 (7.0)	
	Increase 26-74%	19 (4.4)	
	Increase $\geq 75\%$	16 (3.7)	
<i>Don't know</i>	40 (9.3)		
<i>Not applicable to my practice</i>		232 (53.8)	
Radiation	Decrease $\geq 75\%$	7 (1.6)	
	Decrease 26-74%	13 (3.0)	
	Decrease $\leq 25\%$	39 (9.1)	
	Unaffected	34 (7.9)	
	Increase $\leq 25\%$	27 (6.3)	

	Increase 26-74%	21 (4.9)	
	Increase \geq 75%	12 (2.8)	
	<i>Don't know</i>	42 (9.7)	
	<i>Not applicable to my practice</i>	236 (54.8)	
Q39 Cancellations / postponements of treatment procedures	Cold knife conization	Yes	58 (13.5)
		No	99 (23.0)
		<i>Don't know</i>	63 (14.6)
		<i>Not applicable to my practice</i>	211 (49.0)
	Other excisional	Yes	102 (23.7)
		No	78 (18.1)
		<i>Don't know</i>	62 (14.4)
		<i>Not applicable to my practice</i>	188 (43.9)
	Ablative procedures	Yes	84 (19.5)
		No	81 (18.8)
		<i>Don't know</i>	54 (12.5)
		<i>Not applicable to my practice</i>	212 (49.2)
	Hysterectomy	Yes	91 (21.1)
		No	79 (18.3)
		<i>Don't know</i>	61 (14.2)
		<i>Not applicable to my practice</i>	200 (46.4)
	Chemotherapy	Yes	45 (10.4)
		No	82 (19.0)
		<i>Don't know</i>	69 (16.0)
	<i>Not applicable to my practice</i>	235 (54.5)	
Radiation	Yes	50 (11.6)	
	No	72 (16.7)	
	<i>Don't know</i>	72 (16.7)	
	<i>Not applicable to my practice</i>	237 (55.0)	
Q40 Percentage of scheduled treatment procedures that were cancelled	Cold knife conization	0%	37 (8.6)
		1-24%	34 (7.9)
		25-49%	47 (10.9)
		50-74%	29 (6.7)
		\geq 75%	29 (6.7)
		<i>Don't know</i>	52 (12.1)
		<i>Not applicable to my practice</i>	203 (47.3)
	Other excisional	0%	44 (10.2)
		1-24%	43 (10.0)
		25-49%	47 (10.9)
50-74%		40 (9.3)	
\geq 75%		22 (5.1)	
	<i>Don't know</i>	50 (11.6)	
	<i>Not applicable to my practice</i>	185 (42.9)	
Ablative procedures	0%	35 (8.1)	
	1-24%	22 (5.1)	
	25-49%	49 (11.4)	
	50-74%	31 (7.2)	
	\geq 75%	30 (7.0)	
	<i>Don't know</i>	59 (13.7)	
	<i>Not applicable to my practice</i>	205 (47.6)	
Hysterectomy	0%	40 (9.3)	
	1-24%	36 (8.4)	
	25-49%	40 (9.3)	
	50-74%	35 (8.1)	
	\geq 75%	31 (7.2)	
	<i>Don't know</i>	54 (12.5)	


	<i>Not applicable to my practice</i>	195 (45.2)
	0%	20 (4.7)
	1-24%	36 (8.4)
	25-49%	36 (8.4)
Chemotherapy	50-74%	34 (7.9)
	≥75%	20 (4.6)
	<i>Don't know</i>	57 (13.2)
	<i>Not applicable to my practice</i>	228 (52.9)
	0%	21 (4.9)
	1-24%	33 (7.7)
	25-49%	36 (8.4)
Radiation	50-74%	32 (7.4)
	≥75%	26 (6.0)
	<i>Don't know</i>	53 (12.3)
	<i>Not applicable to my practice</i>	230 (53.4)
	0%	26 (6.0)
	1-24%	46 (10.7)
	25-49%	46 (10.7)
Cold knife conization	50-74%	37 (8.6)
	≥75%	20 (4.7)
	<i>Don't know</i>	52 (12.1)
	<i>Not applicable to my practice</i>	204 (47.3)
	0%	24 (5.6)
	1-24%	57 (13.2)
	25-49%	48 (11.1)
Other excisional	50-74%	37 (8.6)
	≥75%	27 (6.3)
	<i>Don't know</i>	53 (12.3)
	<i>Not applicable to my practice</i>	185 (42.9)
	0%	20 (4.6)
	1-24%	42 (9.7)
	25-49%	37 (8.6)
Ablative procedures	50-74%	37 (8.6)
	≥75%	35 (8.1)
	<i>Don't know</i>	54 (12.5)
	<i>Not applicable to my practice</i>	206 (47.8)
	0%	21 (4.9)
	1-24%	44 (10.2)
	25-49%	45 (10.4)
Hysterectomy	50-74%	41 (9.5)
	≥75%	27 (6.3)
	<i>Don't know</i>	59 (13.7)
	<i>Not applicable to my practice</i>	194 (45.0)
	0%	20 (4.6)
	1-24%	39 (9.1)
	25-49%	40 (9.3)
Chemotherapy	50-74%	25 (5.8)
	≥75%	26 (6.0)
	<i>Don't know</i>	55 (12.8)
	<i>Not applicable to my practice</i>	226 (52.4)
	0%	19 (4.4)
	1-24%	32 (7.4)
	25-49%	33 (7.7)
Radiation	50-74%	37 (8.6)
	≥75%	21 (4.9)
	<i>Don't know</i>	62 (14.4)

Q41 Percentage of **scheduled treatment procedures** that were **postponed**

	<i>Not applicable to my practice</i>	227 (52.7)
	1 week to <2 weeks	13 (3.0)
	2 weeks to <4 weeks	31 (7.2)
	1 month to <2 months	32 (7.4)
	2 months to <4 months	42 (9.7)
	4 months to <6 months	33 (7.7)
	>6 months	13 (3.0)
	<i>Don't know</i>	48 (11.1)
	<i>Not applicable to my practice</i>	219 (50.8)
	1 week to <2 weeks	19 (4.4)
	2 weeks to <4 weeks	32 (7.4)
	1 month to <2 months	52 (12.1)
	2 months to <4 months	33 (7.7)
	4 months to <6 months	33 (7.7)
	>6 months	16 (3.7)
	<i>Don't know</i>	48 (11.1)
	<i>Not applicable to my practice</i>	198 (45.9)
	1 week to <2 weeks	17 (3.9)
	2 weeks to <4 weeks	18 (4.2)
	1 month to <2 months	40 (9.3)
	2 months to <4 months	42 (9.7)
	4 months to <6 months	30 (7.0)
	>6 months	20 (4.6)
	<i>Don't know</i>	50 (11.6)
	<i>Not applicable to my practice</i>	214 (49.7)
	1 week to <2 weeks	21 (4.9)
	2 weeks to <4 weeks	23 (5.3)
	1 month to <2 months	31 (7.2)
	2 months to <4 months	46 (10.7)
	4 months to <6 months	30 (7.0)
	>6 months	20 (4.6)
	<i>Don't know</i>	55 (12.8)
	<i>Not applicable to my practice</i>	205 (47.6)
	1 week to <2 weeks	19 (4.4)
	2 weeks to <4 weeks	28 (6.5)
	1 month to <2 months	32 (7.4)
	2 months to <4 months	27 (6.3)
	4 months to <6 months	28 (6.5)
	>6 months	22 (5.1)
	<i>Don't know</i>	49 (11.4)
	<i>Not applicable to my practice</i>	226 (52.4)
	1 week to <2 weeks	17 (3.9)
	2 weeks to <4 weeks	28 (6.5)
	1 month to <2 months	29 (6.7)
	2 months to <4 months	36 (8.4)
	4 months to <6 months	25 (5.8)
	>6 months	11 (2.6)
	<i>Don't know</i>	55 (12.8)
	<i>Not applicable to my practice</i>	230 (53.4)

Q42 Length of deferral period for postponed treatment procedures

Supplementary Figures



Supplementary Figure 1: Cancelled (n = 325) and postponed (n = 382) screening appointments by province that were cancelled or postponed by physician/providers' institution, by patient, or converted to telemedicine

Supplementary Figure 1 legend:

Number cancelled by (A) physician or providers' institution, (B) patient, and (C) converted to telemedicine.

Number postponed by (D) physician or providers' institution, (E) patient, and (F) converted to telemedicine.


Answers include responses for questions 7 (cancellations) and 9 (postponements) by question 2 (province).

Respondents were asked to ensure that their answers did not exceed 100% for each question. (i.e., for each respondent, $A + B + C \approx 100\%$ and $D + E + F \approx 100\%$).

The **x axis** represents frequency of responses by province. Territories include Northwest Territories, Nunavut, and Yukon. Other provinces include Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Quebec, and Saskatchewan (and one respondent who preferred not to say).

The **y axis** represents cancelled or postponed screening appointments using a predefined interval scale.

DK: Don't know



Supplementary Figure 2: Cancelled (n = 325) and postponed (n = 382) screening appointments by profession that were cancelled or postponed by physician/providers’ institution, by patient, or converted to telemedicine


Supplementary Figure 2 legend:

Number cancelled by (A) physician or providers’ institution, (B) patient, and (C) converted to telemedicine. Number postponed by (D) physician or providers’ institution, (E) patient, and (F) converted to telemedicine. Answers include responses for questions 7 (cancellations) and 9 (postponements) by question 4 (profession). Respondents were asked to ensure that their answers did not exceed 100% for each question. (i.e., for each respondent, A + B + C ≈ 100% and D + E + F ≈ 100%).

The x axis represents frequency of responses by profession. Primary includes general practitioners/family physicians, nurse practitioners/registered nurses, physician assistants and a manager of a community hospital; Secondary (clinical) includes colposcopists and colposcopy registered nurses/registered practical nurses; Secondary (cytological) includes cytopathologists/technologists and pathologists; Tertiary includes gynecologists/obstetrician-gynecologists, gynecology oncologists, and gynecology nurses. Frequency count exceeded total number of respondents as some reported multiple professions.

The y axis represents cancelled or postponed screening appointments using a predefined interval scale.

DK: Don’t know



Supplementary Figure 3: Cancelled (n = 325) and postponed (n = 382) screening appointments by place of practice that were cancelled or postponed by physician/providers' institution, by patient, or converted to telemedicine


Supplementary Figure 3 legend:

Number cancelled by (A) physician or providers' institution, (B) patient, and (C) converted to telemedicine. Number postponed by (D) physician or providers' institution, (E) patient, and (F) converted to telemedicine. Answers include responses for questions 7 (cancellations) and 9 (postponements) by question 5 (place of practice). Respondents were asked to ensure that their answers did not exceed 100% for each question. (i.e., for each respondent, A + B + C ≈ 100% and D + E + F ≈ 100%).

The x axis represents frequency of responses by place of practice. Frequency count exceeded total number of respondents as some reported multiple places of practice.

The y axis represents cancelled or postponed screening appointments using a predefined interval scale.

DK: Don't know



Supplementary Figure 4: Cancelled (n = 114) and postponed (n = 167) **colposcopy** appointments by **province** that were cancelled or postponed by physician/providers' institution or by patient

Supplementary Figure 4 legend:

Number cancelled by (A) physician or providers' institution and (B) patient.

Number postponed by (C) physician or providers' institution and (D) patient.


Answers include responses for questions 26 (cancellations) and 28 (postponements) by question 2 (province).

Respondents were asked to ensure that their answers did not exceed 100% for each question. (i.e., for each respondent, A + B ≈ 100% and C + D ≈ 100%).

The **x axis** represents frequency of responses by province. Territories include Northwest Territories, Nunavut, and Yukon. Other provinces include Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Quebec, and Saskatchewan (and one respondent who preferred not to say).

The **y axis** represents cancelled or postponed colposcopy appointments using a predefined interval scale.

DK: Don't know



Supplementary Figure 5: Cancelled (n = 114) and postponed (n = 167) colposcopy appointments by profession that were cancelled or postponed by physician/providers' institution or by patient

Supplementary Figure 5 legend:

Number cancelled by (A) physician or providers' institution and (B) patient.

Number postponed by (C) physician or providers' institution and (D) patient.


Answers include responses for questions 26 (cancellations) and 28 (postponements) by question 4 (profession).

Respondents were asked to ensure that their answers did not exceed 100% for each question. (i.e., for each respondent, A + B ≈ 100% and C + D ≈ 100%).

The **x axis** represents frequency of responses by profession. Primary includes general practitioners/family physicians, nurse practitioners/registered nurses, and physician assistants; Secondary (clinical) includes colposcopists and colposcopy registered nurses/registered practical nurses; Secondary (cytological) includes cytopathologists/technologists and pathologists; Tertiary includes gynecologists/obstetrician-gynecologists, gynecology oncologists, and gynecology nurses. Frequency count exceeded total number of respondents as some reported multiple professions.

The **y axis** represents cancelled or postponed colposcopy appointments using a predefined interval scale.

DK: Don't know



Supplementary Figure 6: Cancelled (n = 114) and postponed (n = 167) colposcopy appointments by place of practice that were cancelled or postponed by physician/providers' institution or by patient

Supplementary Figure 6 legend:

Number cancelled by (A) physician or providers' institution and (B) patient.


Number postponed by (C) physician or providers' institution and (D) patient.

Answers include responses for questions 26 (cancellations) and 28 (postponements) by question 5 (place of practice). Respondents were asked to ensure that their answers did not exceed 100% for each question. (i.e., for each respondent, A + B ≈ 100% and C + D ≈ 100%).

The **x axis** represents frequency of responses by place of practice. Frequency count exceeded total number of respondents as some reported multiple places of practice.

The **y axis** represents cancelled or postponed colposcopy appointments using a predefined interval scale.

DK: Don't know



Supplementary Figure 7: Cancelled (n = 148) and postponements (n = 238) of **follow-up** appointments by **province** that were cancelled or postponed by physician/providers' institution, by patient, or converted to telemedicine


Supplementary Figure 7 legend:

Number cancelled by (A) physician or providers' institution, (B) patient and (C) converted to telemedicine. Number postponed by (D) physician or providers' institution, (E) patient and (F) converted to telemedicine. Answers include responses for questions 32 (cancellations) and 34 (postponements) by question 2 (province). Respondents were asked to ensure that their answers did not exceed 100% for each question. (i.e., for each respondent, A + B + C ≈ 100% and D + E + F ≈ 100%).

The **x axis** represents frequency of responses by province. Territories include Northwest Territories, Nunavut, and Yukon. Other provinces include Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Quebec, and Saskatchewan (and one respondent who preferred not to say).

The **y axis** represents cancelled or postponed follow-up appointments using a predefined interval scale.

DK: Don't know



Supplementary Figure 8: Cancelled (n = 148) and postponed (n = 238) follow-up appointments by profession that were cancelled or postponed by physician/providers' institution, by patient, or converted to telemedicine


Supplementary Figure 5 legend:

Number cancelled by (A) physician or providers' institution, (B) patient and (C) converted to telemedicine. Number postponed by (D) physician or providers' institution, (E) patient and (F) converted to telemedicine. Answers include responses for questions 32 (cancellations) and 34 (postponements) by question 4 (profession). Respondents were asked to ensure that their answers did not exceed 100% for each question. (i.e., for each respondent, A + B + C ≈ 100% and D + E + F ≈ 100%).

The x axis represents frequency of responses by profession. Primary includes general practitioners/family physicians, nurse practitioners/registered nurses, and physician assistants; Secondary (clinical) includes colposcopists and colposcopy registered nurses/registered practical nurses; Secondary (cytological) includes cytopathologists/technologists and pathologists; Tertiary includes gynecologists/obstetrician-gynecologists, gynecology oncologists, and gynecology nurses. Frequency count exceeded total number of respondents as some reported multiple professions.

The y axis represents cancelled or postponed follow-up appointments using a predefined interval scale.

DK: Don't know



Supplementary Figure 9: Cancelled (n = 148) and postponed (n = 238) follow-up appointments by place of practice that were cancelled or postponed by physician/providers' institution, by patient, or converted to telemedicine

Supplementary Figure 9 legend:

Number cancelled by (A) physician or providers' institution, (B) patient and (C) converted to telemedicine.


Number postponed by (C) physician or providers' institution, (D) patient and (E) converted to telemedicine.

Answers include responses for questions 32 (cancellations) and 34 (postponements) by question 5 (place of practice). Respondents were asked to ensure that their answers did not exceed 100% for each question. (i.e., for each respondent, A + B + C ≈ 100% and D + E + F ≈ 100%).

The **x axis** represents frequency of responses by place of practice. Frequency count exceeded total number of respondents as some reported multiple places of practice.

The **y axis** represents cancelled or postponed follow-up appointments using a predefined interval scale.

DK: Don't know



Supplementary Figure 10: Responses to **open-ended Q22** by province, profession and place of practice (n = 206)

Supplementary Figure 10 legend:


Opinions and perspectives are shown by (A) province, (B) profession, and (C) place of practice.

Answers include responses for question 22 (COVID-19 to encourage/facilitate/accelerate implementation of HPV self-sampling) by questions 2 (province), 4 (profession) and 5 (place of practice).

Panel A: Territories include Northwest Territories, Nunavut, and Yukon. Other provinces include Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Quebec, and Saskatchewan (and one respondent who preferred not to say).

Panel B: Primary includes general practitioners/family physicians, nurse practitioners/registered nurses, physician assistants and a manager of a community center; Secondary (clinical) includes colposcopists and colposcopy registered nurses/registered practical nurses; Secondary (cytological) includes cytopathologists/technologists and pathologists; Tertiary includes gynecologists/obstetrician-gynecologists, gynecology oncologists, and gynecology nurses.

Panels B and C: Frequency count exceeded total number of respondents as some reported multiple places of practice.



Supplementary Figure 11: Responses to open-ended Q23 by province, profession and place of practice (n = 197)

Supplementary Figure 11 legend:

Opinions and perspectives are shown by (A) province, (B) profession, and (C) place of practice.

Answers include responses for question 23 (in favor of implementing HPV self-sampling as alternative screening method) by questions 2 (province), 4 (profession) and 5 (place of practice).

Panel A: Territories include Northwest Territories, Nunavut, and Yukon. Other provinces include Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Quebec, and Saskatchewan (and one respondent who preferred not to say).

Panel B: Primary includes general practitioners/family physicians, nurse practitioners/registered nurses, physician assistants, and a manager of a community health center; Secondary (clinical) includes colposcopists and colposcopy registered nurses/registered practical nurses; Secondary (cytological) includes cytopathologists/technologists and pathologists; Tertiary includes gynecologists/obstetrician-gynecologists, gynecology oncologists, and gynecology nurses.

Panels B and C: Frequency count exceeded total number of respondents as some reported multiple places of practice.